CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-07). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2421 · Search date 2026-08-07 · Methodology v0.7

Flurbiprofen 8.75 mg lozenge,
does it really help with Relief of acute sore-throat pain and difficulty swallowing?

30-Second Summary
C
Evidence Grade C · 46 · Safety caution
The 8.75 mg lozenge modestly improved acute sore-throat pain, but evidence is limited to short manufacturer trials
Oral pain, stomatitis, paresthesia, throat irritation, abdominal pain, and nausea were reported. Despite the low local dose, NSAID gastrointestinal bleeding, renal and cardiovascular risks, anticoagulant interactions, and hypersensitivity still require caution.
What the
research shows
The grade is C with 46 points. Pain improved more than with a matched inactive lozenge, but the evidence is confined to a manufacturer development program. This verdict is limited to the 8.75 mg lozenge, not systemic flurbiprofen tablets or injections.
What the
ads claim
Korean pharmacy sore-throat products are locally dissolved lozenges. Evidence from systemic flurbiprofen must not be substituted for this formulation.
*

Useful facts when choosing a product

  • The judged formulation contains flurbiprofen 8.75 mg per lozenge.
  • The control was a matched inactive sugar-based lozenge.
  • Verdict 1698 is D with 34 points for oral dexamethasone, verdict 1722 is B with 68 points for tonsillectomy, and verdict 458 is D with 28 points for probiotic recurrence prevention; these are different interventions and aims.
Gap Measurement · Verdict 2421 · C 46
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

NCT01048866 randomized 198 adults, 101 versus 97, to flurbiprofen 8.75 mg or a sugar-based placebo lozenge every 3-6 hours, up to five in 24 hours. The primary endpoint was 24-hour time-weighted SPID; 194 participants were evaluable. Two-hour swallowing-difficulty sums were -37.1 (SD 39.60) versus -18.1 (SD 29.43). The study belonged to the Reckitt Benckiser Healthcare International development program.

02

Why this is classified as C (46)

Patient-reported pain improved, but magnitude was about 0.45 SD and the small evidence base was manufacturer-only, giving C with 46 points. Follow-up was appropriate for acute sore throat.

Counterpoint. C does not mean no analgesic action; it marks limited independence, duration, size, and clinical interpretability.

Rejudgment record. Cross-check applied — Placebo-lozenge comparison, 24-hour SPID, Cohen's statistical magnitude convention, manufacturer funding, and small trials

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE~Statistically positive but below the threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Relief of sore-throat pain over 24 hoursCThe result favored active lozenges, with a standardized magnitude of about 0.45.
Relief of difficulty swallowingCThe two-hour summed values were -37.1 versus -18.1.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Multicenter double-blind placebo-controlled randomized trial95Reckitt Benckiser Healthcare International manufacturer development programTime-weighted 24-hour sum of sore-throat pain-intensity differences-522.9 (SD 476.54) versus -326.5 (SD 386.83) mm-hours; adjusted difference -196.6 (95% CI -321.0 to -72.2)Pivotal placebo-controlled efficacy evidence
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-08-07).

Schachtel BP, Aspley S, Shephard A, Shea T, Smith G, Schachtel E. Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study. Trials. 2014;15:263. PMID: 24988909. DOI: 10.1186/1745-6215-15-263.
checked
ClinicalTrials.gov. NCT01048866. A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis.
checked
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-07 · Corrections: none

Cite this verdict

Flurbiprofen 8.75 mg lozenge x acute sore-throat relief Evidence Grade C card
[Chamgap] Flurbiprofen 8.75 mg lozenge x acute sore-throat relief — Evidence Grade C·46. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/flurbiprofen-8-75mg-lozenge-acute-sore-throat-relief/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.